Literature DB >> 12619028

Membrane barrier of a porcine hepatocyte bioartificial liver.

Scott L Nyberg1, Toshikazu Yagi, Takakazu Matsushita, Joseph Hardin, Joseph P Grande, Lawrence E Gibson, Jeffrey L Platt.   

Abstract

Pores in the membrane of a bioartificial liver (BAL) allow it to function as a semipermeable barrier between its contents (i.e., liver cells) and components of the recipient's immune system. This study is designed to assess the influence of pore size on immune response to a BAL containing porcine hepatocytes. Sixteen healthy dogs were divided into four groups (four dogs per group) based on pore size of the BAL membrane and level of exposure to porcine hepatocytes. Group 1 dogs were administered porcine hepatocytes by intraperitoneal injection and served as positive controls. Group 2 dogs were exposed to porcine hepatocytes in a large-pore (200-nm) BAL, and group 3 dogs were exposed to porcine hepatocytes in a small-pore (10-nm) BAL. Group 4 dogs were exposed to a no-cell (unloaded) BAL and served as negative controls. Intraperitoneal injection of hepatocytes or 3 hours of BAL hemoperfusion was performed day 0 and 3 weeks later on day 21. Biochemical, humoral, and cellular measures of immune response were collected until day 44. The initiation of BAL hemoperfusion was associated with a rapid decline in CH(50) levels of complement and transient neutropenia and thrombocytopenia during all BAL exposures. Xenoreactive antibody response to BAL was increased by use of membranes with large pores and secondary exposures. Skin testing on day 42 showed a delayed-type hypersensitivity response to porcine hepatocytes that also correlated with level of previous antigen exposure. BAL treatment was associated with both immediate and elicited immunologic responses. The immediate response was transient and not influenced by membrane pore size, whereas elicited responses were influenced by pore size of the BAL during previous exposures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619028     DOI: 10.1053/jlts.2003.50024

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

Review 1.  Cell therapies for liver diseases.

Authors:  Yue Yu; James E Fisher; Joseph B Lillegard; Brian Rodysill; Bruce Amiot; Scott L Nyberg
Journal:  Liver Transpl       Date:  2012-01       Impact factor: 5.799

2.  Pivotal preclinical trial of the spheroid reservoir bioartificial liver.

Authors:  Jaime M Glorioso; Shennen A Mao; Brian Rodysill; Taufic Mounajjed; Walter K Kremers; Faysal Elgilani; Raymond D Hickey; Hakon Haugaa; Christopher F Rose; Bruce Amiot; Scott L Nyberg
Journal:  J Hepatol       Date:  2015-03-25       Impact factor: 25.083

3.  Pig-to-baboon liver xenoperfusion utilizing GalTKO.hCD46 pigs and glycoprotein Ib blockade.

Authors:  John C LaMattina; Lars Burdorf; Tianshu Zhang; Elana Rybak; Xiangfei Cheng; Raghava Munivenkatappa; Isabelle I Salles; Katleen Broos; Evelyn Sievert; Brian McCormick; Marc Decarlo; David Ayares; Hans Deckmyn; Agnes M Azimzadeh; Richard N Pierson; Rolf N Barth
Journal:  Xenotransplantation       Date:  2014-03-17       Impact factor: 3.907

4.  Optimization of mass transfer for toxin removal and immunoprotection of hepatocytes in a bioartificial liver.

Authors:  Geir I Nedredal; Bruce P Amiot; Peter Nyberg; Jennifer Luebke-Wheeler; Joseph B Lillegard; Travis J McKenzie; Scott L Nyberg
Journal:  Biotechnol Bioeng       Date:  2009-12-01       Impact factor: 4.530

5.  Polymerizable superoxide dismutase mimetic protects cells encapsulated in poly(ethylene glycol) hydrogels from reactive oxygen species-mediated damage.

Authors:  Patrick S Hume; Kristi S Anseth
Journal:  J Biomed Mater Res A       Date:  2011-07-25       Impact factor: 4.396

6.  Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure.

Authors:  Yi Li; Qiong Wu; Yujia Wang; Chengxin Weng; Yuting He; Mengyu Gao; Guang Yang; Li Li; Fei Chen; Yujun Shi; Bruce P Amiot; Scott L Nyberg; Ji Bao; Hong Bu
Journal:  Theranostics       Date:  2018-11-09       Impact factor: 11.556

7.  A preliminary study for constructing a bioartificial liver device with induced pluripotent stem cell-derived hepatocytes.

Authors:  Masaya Iwamuro; Hidenori Shiraha; Shuhei Nakaji; Masumi Furutani; Naoya Kobayashi; Akinobu Takaki; Kazuhide Yamamoto
Journal:  Biomed Eng Online       Date:  2012-12-07       Impact factor: 2.819

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.